Featured Content

Latest Press Releases

Sep 21, 2021 Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Rare Disease Diagnosis
Sep 16, 2021 Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work®
Sep 07, 2021 Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)

See All Press Releases

Statements

Our Commitment to Anti-Racism
Statement on TEPEZZA^® (teprotumumab-trbw) Availability

Named Patient Use Programs

Named Patient Use Program for TEPEZZA® (teprotumumab-trbw)
Named Patient Use Program for UPLIZNA® (inebilizumab-cdon)

Featured Videos

The Horizon Story

The Horizon Story

Deidre Lindsey

Deidre Lindsey

#RAREis: Francis’ Rare Disease Adoption Story in Song

#RAREis: Francis’ Rare Disease Adoption Story in Song

Giving Back is Personal

Giving Back is Personal

Corporate Brochure

Corporate Brochure

Fact Sheets & Downloads

See All Fact Sheets

Logo Download

Download Horizon Logo | RGB Full Color (.jpg)
Download Horizon Logo | RGB Full Color (.png)
Download Horizon Logo | Charcoal Single Color (.jpg)
Download Horizon Logo | Charcoal Single Color (.png)

If you are looking for additional Horizon media assets, please contact corpcomms@horizontherapeutics.com

Media Inquiries

For U.S. media inquiries, contact:
Geoff Curtis
Senior Vice President, Corporate Affairs
media@horizontherapeutics.com
+1 (888) 506-2562

For EU media inquiries, contact:
Ray Gordon
Managing Director
ray@gordonmrm.ie
+353 (87) 2417373